Phenotypic and genotypic aminoglycoside resistance in blood culture isolates of coagulase-negative staphylococci from a single neonatal intensive care unit, 1989–2000
Open Access
- 1 November 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 54 (5), 889-896
- https://doi.org/10.1093/jac/dkh453
Abstract
Objectives: To investigate the prevalence of aminoglycoside resistance and genes encoding aminoglycoside-modifying enzymes (AME) in blood culture isolates of coagulase-negative staphylococci (CoNS) from neonates. Materials and methods: A total of 180 isolates from 148 patients collected in a single neonatal unit over a 12 year period were examined for susceptibility to gentamicin, tobramycin, netilmicin, amikacin and arbekacin by Etest and/or disc diffusion. AME genes were detected by PCR. Results: The overall non-susceptibility rates to gentamicin, tobramycin, netilmicin, amikacin and arbekacin were 66%, 68%, 52%, 38% and 1%, respectively. Gentamicin non-susceptibility rates were 4% and 91% in methicillin-susceptible and -resistant isolates, respectively. aac(6′)-Ie-aph(2″)-Ia, aph(3′)-IIIa and/or ant(4′)-Ia were encountered in 125 (69%), 1 (0.5%) and 30 (16.6%) isolates, respectively. Forty-six (26%) isolates negative for AME genes were susceptible to all aminoglycosides. In contrast, 115 (92%), 91 (73%) and 66 (53%) of aac(6′)-Ie-aph(2″)-Ia positive isolates were non-susceptible to gentamicin, netilmicin and amikacin, respectively. Only one isolate showed arbekacin resistance. However, aac(6′)-Ie-aph(2″)-Ia positive isolates and isolates with gentamicin MIC ≥128 mg/L displayed a significant reduction in arbekacin inhibition zones. Conclusions: A high prevalence of aminoglycoside resistance was detected and associated with methicillin resistance. Discrepancies between phenotypic and genetic detection of aminoglycoside resistance were discerned. Gentamicin was the preferred substrate for phenotypic detection of aac(6′)-Ie-aph(2″)-Ia. Arbekacin showed favourable antibacterial activity even in aac(6′)-Ie-aph(2″)-Ia-positive isolates. We suggest including arbekacin in future clinical trials of empirical treatment of late onset neonatal sepsis.Keywords
This publication has 37 references indexed in Scilit:
- A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal unitsArchives of Disease in Childhood: Fetal & Neonatal, 2003
- Multiplex PCR for the Detection of Genes Encoding Aminoglycoside Modifying Enzymes and Methicillin Resistance among Staphylococcus SpeciesJournal of Korean Medical Science, 2003
- Identification of Aminoglycoside-Modifying Enzymes by Susceptibility Testing: Epidemiology of Methicillin-Resistant Staphylococcus aureus in JapanJournal of Clinical Microbiology, 2001
- Nosocomial Coagulase Negative Staphylococcal (CoNS) Catheter-Related Sepsis in Preterm Infants: Definition, Diagnosis, Prophylaxis, and PreventionJournal of Perinatology, 2001
- Clinical and laboratory impact of coagulase‐negative staphylococci bacteremia in preterm infantsActa Paediatrica, 2000
- Rationing antibiotic use in neonatal unitsArchives of Disease in Childhood: Fetal & Neonatal, 2000
- Antimicrobial susceptibility of coagulase-negative staphylococci isolated between 1991 and 1996 from a German university hospitalClinical Microbiology & Infection, 1999
- The Source of Coagulase-Negative Staphylococci in the Endophthalmitis Vitrectomy StudyArchives of Ophthalmology (1950), 1997
- The Most Frequent Aminoglycoside Resistance Mechanisms--Changes with Time and Geographic Area: A Reflection of Aminoglycoside Usage Patterns?Clinical Infectious Diseases, 1997
- Antimicrobial susceptibility of coagulase-negative staphylococciAntimicrobial Agents and Chemotherapy, 1994